Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage IA2-IA3 Nonsmall Cell Lung Cancer, following Complete Tumour Resection - ADAURA2

ASTRAZENECA AB0 个研究点目标入组 380 人开始时间: 2021年12月30日最近更新: 2022年4月4日

试验速览

暂无简介。

•1. Male or female, at least >= 18 years.
•2. NSCLC, of non-squamous histology.
•3. Stage IA2 or IA3 disease, based on TNM8 classification.
•4. Complete surgical resection (R0) of the primary NSCLC by lobectomy, segmentectomy or sleeve resection.
•5. Complete recovery from surgery at the time of randomisation. Study intervention cannot commence within 4 weeks following surgery. No more than 12 weeks may have elapsed between surgery and randomisation for participants.
•6. World Health Organization performance status of 0 or 1.
•7. Provision of tumour sample for central pathology assessment of pathologic risk factors and to assess EGFR mutation status prior to randomisation.
•8. A tumour which harbours one of the 2 EGFR mutations (Ex19del, L858R).
•9. Minimum life expectancy of > 6 months.
•10. Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential, or must have evidence of non-child-bearing potential. Male subjects must be willing to use barrier contraception.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 190
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 190

•1. Mixed small cell and non-small cell cancer history.
•2. Participants with incomplete (R1/R2) resection, or who have undergone pneumonectomy, bilobectomy or only wedge resection.
•3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and HIV.
•4. History of another primary malignancy except for malignancy treated with curative intent with no known active disease = 5 years before the first dose of study intervention and of low potential risk for recurrence.
•5. Any of the following cardiac criteria:
•- Mean resting QTc interval > 470 ms, obtained from triplicate ECGs performed at screening,
•- Any abnormalities in rhythm, conduction, or morphology of resting ECG,
•- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events.
•6. History of interstitial lung disease.
•7. Inadequate bone marrow reserve or organ function.
•8. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study intervention.
•9. Prior treatment with any anticancer therapy for NSCLC (including chemotherapy, radiotherapy, immunotherapy, and EGFR-TKIs).
•10. Major surgery or significant traumatic injury within 4 weeks of the first dose of study intervention.
•11. Participants currently receiving medications or herbal supplements known to be strong inducers of CYP3A4.

发起方